Symtuza (emtricitabine tenofovir alafenamide cobicistat darunavir ethanolate): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Symtuza 800 mg/150 mg/200 mg/10 mg film coated tablets

Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).

Genotypic testing should guide the use of Symtuza (see sections 4.2 and 5.1).


Route of administration: Oral
Molecule: emtricitabine, tenofovir alafenamide, cobicistat, darunavir ethanolate

Patients' opinions on Symtuza

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

HIV/AIDS

See the fact sheet